What is the level of liabilities of HLB Life Science Co this year?
HLB Life Science Co has a debt balance of 0 KRW this year.
In 2024, HLB Life Science Co's total liabilities amounted to 0 KRW, a -100% difference from the 177.07 B KRW total liabilities in the previous year.
HLB Life Science Co's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating HLB Life Science Co's financial stability, operational efficiency, and long-term viability.
By comparing HLB Life Science Co's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
HLB Life Science Co's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Shifts in HLB Life Science Co’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
HLB Life Science Co has a debt balance of 0 KRW this year.
The liabilities of HLB Life Science Co have increased by -100% dropped compared to the previous year.
High liabilities can pose a risk for investors of HLB Life Science Co, as they can weaken the company's financial position and impair its ability to meet its obligations.
Low liabilities mean that HLB Life Science Co has a strong financial position and is able to meet its obligations without overburdening its finances.
An increase in liabilities of HLB Life Science Co can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
A decrease in the liabilities of HLB Life Science Co can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
Some factors that can influence the liabilities of HLB Life Science Co include investments, acquisitions, operating costs, and sales development.
The liabilities of HLB Life Science Co are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
To change its liabilities, HLB Life Science Co can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
Over the past 12 months, HLB Life Science Co paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, HLB Life Science Co is expected to pay a dividend of 0 KRW.
The current dividend yield of HLB Life Science Co is .
HLB Life Science Co pays a quarterly dividend. This is distributed in the months of .
HLB Life Science Co paid dividends every year for the past 0 years.
For the upcoming 12 months, dividends amounting to 0 KRW are expected. This corresponds to a dividend yield of 0 %.
HLB Life Science Co is assigned to the 'Health' sector.
To receive the latest dividend of HLB Life Science Co from 8/7/2024 amounting to 0 KRW, you needed to have the stock in your portfolio before the ex-date on 8/7/2024.
The last dividend was paid out on 8/7/2024.
In the year 2023, HLB Life Science Co distributed 0 KRW as dividends.
The dividends of HLB Life Science Co are distributed in KRW.
Our stock analysis for HLB Life Science Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of HLB Life Science Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.